WaveMan
WaveMan · Company
MBX · Mbx Biosciences, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

MBX MBX Biosciences (MBX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001776111
Quote by TradingView
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
101
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $815.3K priced

What the filings say about MBX

Insiders, 180 days
-$2.7M net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$341.6K
3 notices

MBX Biosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, MBX Biosciences, Inc. insiders sold a net $2.7M of stock across 36 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Azoulay Salomon
Chief Medical Officer
SELL
2026-08-05 SECtraded 2026-08-04
370
$24.3K
-25.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on May 8, 2026.
  • The trade is 2.6% of the 14,399 shares held after it.
  • No other insider sold within 30 days.
  • 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Azoulay Salomon sold about $24.3K of MBX on Aug 4, 2026; 101 funds added in the latest 13F quarter.
Azoulay Salomon
Chief Medical Officer
SELL
2026-05-11 SECtraded 2026-05-08
55,000
$2.1M
+36.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 6, 2026.
  • The trade is 372.4% of the 14,769 shares held after it.
  • 1 other insider sold within 30 days.
  • 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Azoulay Salomon sold about $2.1M of MBX on May 8, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 101 funds added in the latest 13F quarter.
Azoulay Salomon
Chief Medical Officer
SELL
2026-05-11 SECtraded 2026-05-08
15,003
$574.6K
+36.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 6, 2026.
  • The trade is 101.6% of the 14,769 shares held after it.
  • 1 other insider sold within 30 days.
  • 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Azoulay Salomon sold about $574.6K of MBX on May 8, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 101 funds added in the latest 13F quarter.
Azoulay Salomon
Chief Medical Officer
SELL
2026-05-08 SECtraded 2026-05-06
231
$6.8K
+25.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 1.6% of the 14,769 shares held after it.
  • 1 other insider sold within 30 days.
  • 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Azoulay Salomon sold about $6.8K of MBX on May 6, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 101 funds added in the latest 13F quarter.
Hawryluk P. Kent
President & CEO
SELL
2026-05-08 SECtraded 2026-05-06
607
$17.9K
+25.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Mar 13, 2026.
  • +33.0% median (+82.2% mean) 90-day return after 3 previous buys.
  • The trade is 0.1% of the 727,667 shares held after it.
  • 1 other insider sold within 30 days.
  • 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Hawryluk P. Kent sold about $17.9K of MBX on May 6, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 101 funds added in the latest 13F quarter.
36 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 31 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$2.7M over 180 days
-$24.3K over 90 days
below 73% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
101 funds bought in last quarter
more than 68% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
14.4% of the float short (float per yahoo 2026-10-26) · 6.8 days to cover · settled 2026-09-30
more than 68% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch MBX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+211.8%12M
+0%+113%+226%+338%2025-102025-122026-022026-042026-062026-082026-10 2026-05-08 · Azoulay Salomon sold $2.1M2026-05-08 · Azoulay Salomon sold $574.6K2026-03-13 · Hawryluk P. Kent bought $525.6K2026-08-04 · Azoulay Salomon sold $24.3K2026-05-06 · Hawryluk P. Kent sold $17.9K2026-05-06 · Azoulay Salomon sold $6.8K2026-08-17 · Hawryluk P. Kent filed to sell $255.7K2026-08-04 · Azoulay Salomon filed to sell $24.3K2026-08-04 · Hawryluk P. Kent filed to sell $61.6K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MBX: institutional holders (13F)

13F holdings, latest reported quarter
Frazier Life Sciences Management, L.P.
6,652,013 sh
$367.2M
FMR LLC
5,322,885 sh
$293.8M
WELLINGTON MANAGEMENT GROUP LLP
4,977,523 sh
$274.8M
NEA Management Company, LLC
3,614,486 sh
$199.5M
ORBIMED ADVISORS LLC
3,428,736 sh
$189.3M

Congress trades in MBX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MBX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Hawryluk P. Kent
Filed 2026-08-17
$255.7K
Azoulay Salomon
Filed 2026-08-04
$24.3K
Hawryluk P. Kent
Filed 2026-08-04
$61.6K

MBX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Roundhill GLP-1 & Weight Loss ETF
$1.5M position · as of 2026-06-30
2.8%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$11.6M position · as of 2026-06-30
2.7%
Eventide Healthcare & Life Sciences Fund
$48.2M position · as of 2026-06-30
2.7%
PROFUND VP PHARMACEUTICALS
$303.6K position · as of 2026-06-30
2.6%
Fidelity Advisor Biotechnology Fund
$53.9M position · as of 2026-07-31
2.5%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$499.7K position · as of 2026-07-31
2.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 1
1 active
3
Phase 2
1 active
1
Phase 3
1 active
What changed recently
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patient
2026-10-08 · Completion moved 2027-05-27 → 2028-05
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $2.7M sold by insiders over 180 days, 101 funds added last quarter, $341.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MBX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$85.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-33.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-31.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-37.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-3.5%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Operating income-$98.1M-$68.2M-$35.3M
Net income-$87.0M-$61.9M-$32.6M
EPS (diluted)-2.38-5.82-31.96
Operating cash flow-$79.9M-$54.7M-$32.0M
Cash$75.3M$49.4M$30.5M
SEC XBRL, fiscal years, as known on 2026-10-28

MBX Stock Sonar score 4/7 axes

Find similar shapesCompare

MBX ranks highest on institutional and government (68th percentile) and profitability (62nd), and lowest on insider conviction (12th), among Pharma & Biotech peers.

Profitability
62
Inputs
  • Return on equity-33.2% · 65 pct, sector of 545
  • Return on assets-31.3% · 59 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-37.3% · 63 pct, sector of 576
Insider conviction
12
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.7M · 25 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
68
Inputs
  • Funds adding, latest quarter101 · 68 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
27
Inputs
  • Short interest, % of float+14.4% · 27 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

MBX filings, in plain words

Are MBX Biosciences insiders buying or selling MBX?

In the 180 days to 2026-10-28, MBX Biosciences insiders were net sellers, a net $2.7M across purchases and sales reported on Form 4, by 2 sellers.

Are there planned insider sales of MBX?

Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $341.6K of stock; the latest, by Hawryluk P. Kent, was filed 2026-08-17.

Read the full summary

In the 180 days to 2026-10-28, MBX Biosciences insiders were net sellers of MBX, a net $2.7M across purchases and sales reported on Form 4 by 2 sellers. None of the 5 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $341.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies